Combinational Administration of Mesenchymal Stem Cell-Derived Exosomes and Metformin Reduces Inflammatory Responses in an In Vitro Model of Insulin Resistance in HepG2 Cells

Investigators showed that mesenchymal stem cell-derived exosomes as an anti-inflammatory agent in combination with metformin could increase the therapeutic efficacy of metformin without needing to change metformin doses by decreasing inflammatory cytokines production, including IL-1, IL-6, and TNF-α and apoptosis in HepG2 cells.